SG11201810469TA - A composition for preventing or mitigating dementia - Google Patents
A composition for preventing or mitigating dementiaInfo
- Publication number
- SG11201810469TA SG11201810469TA SG11201810469TA SG11201810469TA SG11201810469TA SG 11201810469T A SG11201810469T A SG 11201810469TA SG 11201810469T A SG11201810469T A SG 11201810469TA SG 11201810469T A SG11201810469T A SG 11201810469TA SG 11201810469T A SG11201810469T A SG 11201810469TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- jalan
- tunku
- perak
- ipoh
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 206010012289 Dementia Diseases 0.000 title abstract 3
- 230000000116 mitigating effect Effects 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 abstract 1
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 abstract 1
- 241001673102 Jaya Species 0.000 abstract 1
- 241000928591 Ochanostachys amentacea Species 0.000 abstract 1
- 208000004842 Pinta Diseases 0.000 abstract 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 abstract 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 208000011079 pinta disease Diseases 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 229940031439 squalene Drugs 0.000 abstract 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 abstract 1
- 229930003799 tocopherol Natural products 0.000 abstract 1
- 229960001295 tocopherol Drugs 0.000 abstract 1
- 239000011732 tocopherol Substances 0.000 abstract 1
- 235000010384 tocopherol Nutrition 0.000 abstract 1
- 229930003802 tocotrienol Natural products 0.000 abstract 1
- 239000011731 tocotrienol Substances 0.000 abstract 1
- 229940068778 tocotrienols Drugs 0.000 abstract 1
- 235000019148 tocotrienols Nutrition 0.000 abstract 1
- 235000019156 vitamin B Nutrition 0.000 abstract 1
- 239000011720 vitamin B Substances 0.000 abstract 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MYPI2016701846A MY192213A (en) | 2016-05-23 | 2016-05-23 | A composition for preventing or mitigating dementia |
| PCT/MY2016/050046 WO2017204618A1 (en) | 2016-05-23 | 2016-08-17 | A composition for preventing or mitigating dementia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810469TA true SG11201810469TA (en) | 2018-12-28 |
Family
ID=60412508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810469TA SG11201810469TA (en) | 2016-05-23 | 2016-08-17 | A composition for preventing or mitigating dementia |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11357751B2 (ja) |
| EP (1) | EP3463336A4 (ja) |
| JP (2) | JP2019516805A (ja) |
| KR (1) | KR20190016973A (ja) |
| CN (1) | CN109715154A (ja) |
| AU (1) | AU2016408304B2 (ja) |
| MY (1) | MY192213A (ja) |
| PH (1) | PH12018502496A1 (ja) |
| SG (1) | SG11201810469TA (ja) |
| WO (1) | WO2017204618A1 (ja) |
| ZA (1) | ZA201808515B (ja) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3468530A4 (en) | 2016-06-10 | 2020-03-11 | Clarity Cosmetics Inc. | NON-COMEDOGENOUS HAIR AND SCALP CARE FORMULATIONS AND METHOD OF USE |
| JP7186442B2 (ja) * | 2019-04-22 | 2022-12-09 | 国立研究開発法人産業技術総合研究所 | 新規スクアレン誘導体および抗炎症剤 |
| MY196888A (en) * | 2019-11-19 | 2023-05-08 | Hovid Berhad | A composition for managing cadasil |
| EP3831369A1 (en) * | 2019-12-03 | 2021-06-09 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Squalene for the treatment of demyelinating disorders |
| WO2021246861A1 (en) * | 2020-06-04 | 2021-12-09 | Hovid Berhad | Composition for normalisation of fatty liver and method for producing the same |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4326675C2 (de) * | 1993-08-09 | 1996-12-12 | Puetter Medice Chem Pharm | Verwendung einer Kombination aus Folsäure, Vitamin B¶6¶ und Vitamin B¶1¶¶2¶ zur Vorbeugung von Nervendegenerationserkrankungen und Altersdementia |
| US6716451B1 (en) * | 1999-11-30 | 2004-04-06 | Soft Gel Technologies, Inc. | Formulation and delivery method to enhance antioxidant potency of vitamin E |
| CN1203867C (zh) * | 2003-03-11 | 2005-06-01 | 刘威 | 精制海狗油在制备防治老年痴呆药中的应用 |
| US8586109B2 (en) * | 2003-04-10 | 2013-11-19 | American River Nutrition, Inc. | Annatto extract compositions including tocotrienols and tocopherols and methods of use |
| JP2005245419A (ja) * | 2004-03-04 | 2005-09-15 | Hideyo Sasaya | 健康食品 |
| US20110201679A1 (en) * | 2004-05-14 | 2011-08-18 | Rubin Berish Y | Use of Tocotrienols for Elevating IKBKAP Gene Expression and Treating Neurodegenerative Diseases or Disorders |
| WO2007034323A1 (en) * | 2005-09-26 | 2007-03-29 | Gerry Dean Freundl | Composition for use in treatment of hair balding, thinning and loss and method for same |
| US8597640B2 (en) | 2007-10-31 | 2013-12-03 | University Of Massachusetts Lowell | Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging |
| EP2440201A1 (en) * | 2009-06-10 | 2012-04-18 | Energy4life Ag | Methods and compositions for treating insulin resistance, diabetes mellitus type 2, metabolic syndrome and related disorders |
| DE202011004360U1 (de) * | 2010-05-07 | 2011-06-09 | Tavarlin Ag, 64293 | Speiseöl |
| CA2881189A1 (en) * | 2012-08-07 | 2014-02-13 | Buck Institute For Research On Aging | Multi-component formulation for improving neurological function |
| ES2517741B1 (es) * | 2013-04-30 | 2015-09-09 | Lacer, S.A. | Composición para reducir y/o prevenir la caída del cabello y/o estimular su crecimiento |
| FR3010906B1 (fr) * | 2013-09-25 | 2016-12-23 | Expanscience Lab | Extrait lipidique de graines de passiflores |
| MY161634A (en) * | 2013-10-03 | 2017-04-28 | Malaysian Palm Oil Board | A method for producing high lipophilic antioxidants noodle products |
-
2016
- 2016-05-23 MY MYPI2016701846A patent/MY192213A/en unknown
- 2016-08-17 EP EP16903284.4A patent/EP3463336A4/en not_active Withdrawn
- 2016-08-17 JP JP2019514700A patent/JP2019516805A/ja active Pending
- 2016-08-17 CN CN201680087021.9A patent/CN109715154A/zh active Pending
- 2016-08-17 AU AU2016408304A patent/AU2016408304B2/en active Active
- 2016-08-17 KR KR1020187037196A patent/KR20190016973A/ko not_active Application Discontinuation
- 2016-08-17 SG SG11201810469TA patent/SG11201810469TA/en unknown
- 2016-08-17 US US16/304,248 patent/US11357751B2/en active Active
- 2016-08-17 WO PCT/MY2016/050046 patent/WO2017204618A1/en active Search and Examination
-
2018
- 2018-11-26 PH PH12018502496A patent/PH12018502496A1/en unknown
- 2018-12-18 ZA ZA2018/08515A patent/ZA201808515B/en unknown
-
2021
- 2021-05-19 JP JP2021084423A patent/JP2021121613A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN109715154A (zh) | 2019-05-03 |
| ZA201808515B (en) | 2019-08-28 |
| KR20190016973A (ko) | 2019-02-19 |
| AU2016408304A1 (en) | 2018-12-13 |
| MY192213A (en) | 2022-08-08 |
| AU2016408304B2 (en) | 2022-04-07 |
| EP3463336A4 (en) | 2020-03-25 |
| EP3463336A1 (en) | 2019-04-10 |
| JP2021121613A (ja) | 2021-08-26 |
| WO2017204618A1 (en) | 2017-11-30 |
| US20200316017A1 (en) | 2020-10-08 |
| PH12018502496A1 (en) | 2019-04-08 |
| US11357751B2 (en) | 2022-06-14 |
| JP2019516805A (ja) | 2019-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810469TA (en) | A composition for preventing or mitigating dementia | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201803906PA (en) | Control of cellular redox levels | |
| SG11201804443UA (en) | Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201810485SA (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201903483VA (en) | Compositions and methods for treating ezh2-mediated cancer | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201809875VA (en) | Compositions and methods for treating spinal muscular atrophy | |
| SG11201803915UA (en) | Echinomycin formulation, method of making and method of use thereof | |
| SG11201804435SA (en) | Network security agent | |
| SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases |